Answers to commonly asked questions about biosimilar versions of rituximab

The first biosimilar version of rituximab (Truxima®) was approved for use in Europe in February 2017 and was launched in the UK in April 2017. It is licensed for intravenous use in adults with rheumatoid arthritis, granulomatosis with polyangiitis and microscopic polyangiitis, non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukaemia (CLL). This briefing sheet is intended to support prescribers by providing answers to commonly asked questions about the introduction of this medicine.

Acute CareNewsRituximab

Attachments